Logo image of 93M1.DE

MPH HEALTH CARE AG KONV (93M1.DE) Stock Fundamental Analysis

FRA:93M1 - Deutsche Boerse Ag - DE000A289V03 - Common Stock - Currency: EUR

18.95  -0.8 (-4.05%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to 93M1. 93M1 was compared to 52 industry peers in the Pharmaceuticals industry. 93M1 scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 93M1 does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

93M1 had positive earnings in the past year.
93M1 had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: 93M1 reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: 93M1 reported negative operating cash flow in multiple years.
93M1.DE Yearly Net Income VS EBIT VS OCF VS FCF93M1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

The Return On Assets of 93M1 (11.01%) is better than 78.00% of its industry peers.
93M1 has a Return On Equity (11.53%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA 11.01%
ROE 11.53%
ROIC N/A
ROA(3y)11.46%
ROA(5y)-0.71%
ROE(3y)12.15%
ROE(5y)-0.63%
ROIC(3y)N/A
ROIC(5y)N/A
93M1.DE Yearly ROA, ROE, ROIC93M1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

1.3 Margins

The Profit Margin of 93M1 (105749.17%) is better than 100.00% of its industry peers.
93M1's Profit Margin has improved in the last couple of years.
93M1 does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 105749.17%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y32.91%
GM growth 3YN/A
GM growth 5YN/A
93M1.DE Yearly Profit, Operating, Gross Margins93M1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100K -100K

More info and screens

4

2. Health

2.1 Basic Checks

93M1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 93M1 remains at a similar level compared to 1 year ago.
Compared to 5 years ago, 93M1 has about the same amount of shares outstanding.
The debt/assets ratio for 93M1 has been reduced compared to a year ago.
93M1.DE Yearly Shares Outstanding93M1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
93M1.DE Yearly Total Debt VS Total Assets93M1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 4.98 indicates that 93M1 is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.98, 93M1 belongs to the top of the industry, outperforming 82.00% of the companies in the same industry.
93M1 has a debt to FCF ratio of 13.58. This is a negative value and a sign of low solvency as 93M1 would need 13.58 years to pay back of all of its debts.
93M1 has a Debt to FCF ratio of 13.58. This is in the lower half of the industry: 93M1 underperforms 62.00% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that 93M1 is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.02, 93M1 belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 13.58
Altman-Z 4.98
ROIC/WACCN/A
WACC6.91%
93M1.DE Yearly LT Debt VS Equity VS FCF93M1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 0.52 indicates that 93M1 may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.52, 93M1 is doing worse than 86.00% of the companies in the same industry.
93M1 has a Quick Ratio of 0.52. This is a bad value and indicates that 93M1 is not financially healthy enough and could expect problems in meeting its short term obligations.
93M1 has a worse Quick ratio (0.52) than 86.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.52
93M1.DE Yearly Current Assets VS Current Liabilites93M1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.45% over the past year.
Measured over the past years, 93M1 shows a very strong growth in Earnings Per Share. The EPS has been growing by 23.67% on average per year.
Looking at the last year, 93M1 shows a quite strong growth in Revenue. The Revenue has grown by 17.44% in the last year.
93M1 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.95% yearly.
EPS 1Y (TTM)8.45%
EPS 3YN/A
EPS 5Y23.67%
EPS Q2Q%-194.51%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y-4.71%
Revenue growth 5Y-6.95%
Sales Q2Q%39.52%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
93M1.DE Yearly Revenue VS Estimates93M1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
93M1.DE Yearly EPS VS Estimates93M1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 2.53, the valuation of 93M1 can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of 93M1 indicates a rather cheap valuation: 93M1 is cheaper than 100.00% of the companies listed in the same industry.
93M1 is valuated cheaply when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 2.53
Fwd PE N/A
93M1.DE Price Earnings VS Forward Price Earnings93M1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, 93M1 is valued a bit more expensive than 62.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 104.34
EV/EBITDA N/A
93M1.DE Per share data93M1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.11
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 6.08%, 93M1 is a good candidate for dividend investing.
In the last 3 months the price of 93M1 has falen by -22.34%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 3.00, 93M1 pays a better dividend. On top of this 93M1 pays more dividend than 96.00% of the companies listed in the same industry.
93M1's Dividend Yield is rather good when compared to the S&P500 average which is at 2.35.
Industry RankSector Rank
Dividend Yield 6.08%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
93M1.DE Yearly Dividends per share93M1.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DP0%
EPS Next 2YN/A
EPS Next 3YN/A
93M1.DE Yearly Income VS Free CF VS Dividend93M1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

More info and screens

MPH HEALTH CARE AG KONV

FRA:93M1 (7/18/2025, 7:00:00 PM)

18.95

-0.8 (-4.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-09 2025-06-09
Earnings (Next)N/A N/A
Inst Owners0.87%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap81.11M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.08%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 2.53
Fwd PE N/A
P/S 2676.77
P/FCF 104.34
P/OCF 103.78
P/B 0.29
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)7.48
EY39.47%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.18
FCFY0.96%
OCF(TTM)0.18
OCFY0.96%
SpS0.01
BVpS64.92
TBVpS64.92
PEG (NY)N/A
PEG (5Y)0.11
Profitability
Industry RankSector Rank
ROA 11.01%
ROE 11.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 105749.17%
GM N/A
FCFM 2565.35%
ROA(3y)11.46%
ROA(5y)-0.71%
ROE(3y)12.15%
ROE(5y)-0.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y32.91%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 13.58
Debt/EBITDA N/A
Cap/Depr 15.16%
Cap/Sales 13.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 2.43%
Current Ratio 0.52
Quick Ratio 0.52
Altman-Z 4.98
F-Score4
WACC6.91%
ROIC/WACCN/A
Cap/Depr(3y)20.66%
Cap/Depr(5y)19.86%
Cap/Sales(3y)15.7%
Cap/Sales(5y)12.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.45%
EPS 3YN/A
EPS 5Y23.67%
EPS Q2Q%-194.51%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.44%
Revenue growth 3Y-4.71%
Revenue growth 5Y-6.95%
Sales Q2Q%39.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y107.57%
FCF growth 3YN/A
FCF growth 5Y-24.11%
OCF growth 1Y107.61%
OCF growth 3YN/A
OCF growth 5Y-24.28%